FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385667085> ?p ?o ?g. }

• W4385667085 endingPage "e6048802" @default.
• W4385667085 startingPage "e6048802" @default.
• W4385667085 abstract "Topic: 18. Indolent and mantle-cell non-Hodgkin lymphoma - Clinical Background: Targeted therapies (such as Ibrutinib and Venetoclax) have improved Mantle Cell Lymphoma (MCL) patients’ outcomes. OAsIs trial has evaluated the efficacy and toxicity of the Ibrutinib Obinutuzumab plus venetoclax combination in both R/R and untreated MCL patients (NCT02558816, Le Gouill et al. Blood 2021). Aims: We present updated results with extended follow-ups of patients enrolled in OASIS trial. Methods: The OASIS trial was a 3 arms multicenter prospective phase 1/2 trial. Arm A (n=9) enrolled R/R patients who were treated with Obinutuzumab (Obi, 1000mg) and Ibrutinib (Ibru, 560mg). Patients in Arm B (R/R; n=24) and C (newly diagnosed MCL; n=15) were treated with Obi+Ibru+Venetoclax (Ven, 400mg). Patients’ characteristics have been described in the original manuscript. Results: In cohorts A (n=9) and B (n=24), overall response rates were 89% and 71%, respectively. Median Follow-ups were 72 and 48m, the 4-y PFS were 67% and 50%, respectively. No safety signals appeared during long term FU. Patients who progressed were treated with Bendamustine-containing regimen (6 out of 10) and one patient received Odronextamab and anti-CD22xCD3 bispecific antibodies. For Cohort C (n=15), the median follow-up was 46m (36, 49m). Median PFS and DOR were not reached, the estimated 48m-PFS and 36m-DOR were 80% (Figures 1 & 2). Two patients prematurely discontinued, one early PD (after 4m) and one for Adverse Event (neuropathy after 9m). The early PD patient harbored no adverse event, especially no TP53 alteration. One patient with TP53 mutation is still experiencing disease control. One patient experienced atrial fibrillation and one patient had acute cardiac failure. Regarding infections, one patient died of a progressive multifocal leukoencephalopathy after the completion of treatment. Two patients prematurely discontinued the treatment, one patient had a PD at C4 and has subsequently been treated with R-CHOP, one patient relapsed after treatment completion and has been treated with Glofitamab. In all, 2 patients progressed and 1 died in arm C (PML), hence, the 4-y OS is estimated to be 93%.Figure 1. PFS for STEP-C Cohort (MCL patients at diagnosis, treated with Obin-Ibru-Ven, mFU=41m) Summary/Conclusion: The Ibrutinib-Venetoclax-Obinutuzumab triplet is associated with a sustained disease control, in both R/R (4-y PFS of 50%) and newly diagnosed (4y-PFS of 80%) patients presenting with high risk-profiles (no low-MIPI patients were included in the Oasis Trial). The anti-CD20+Ibrutinib vs anti-CD20+Ibrutinib+Venetoclax combinations are currently under investigation in OASIS-II trial (NCT04802590) for untreated patients with MCL. Keywords: Venetoclax, ibrutinib, Targeted therapy, Mantle cell lymphoma" @default.
• W4385667085 created "2023-08-09" @default.
• W4385667085 creator A5010173185 @default.
• W4385667085 creator A5016122215 @default.
• W4385667085 creator A5026531372 @default.
• W4385667085 creator A5031977714 @default.
• W4385667085 creator A5045486705 @default.
• W4385667085 creator A5045707345 @default.
• W4385667085 creator A5051605599 @default.
• W4385667085 creator A5053239525 @default.
• W4385667085 creator A5059022907 @default.
• W4385667085 creator A5062305482 @default.
• W4385667085 creator A5063349306 @default.
• W4385667085 creator A5065205435 @default.
• W4385667085 creator A5078197703 @default.
• W4385667085 creator A5082685353 @default.
• W4385667085 date "2023-08-01" @default.
• W4385667085 modified "2023-10-01" @default.
• W4385667085 title "P1090: LONG TERM FOLLOW-UP OF UNTREATED/RELAPSING MCL PATIENTS WITH THE IBRUTINIB, OBINUTUZUMAB, AND VENETOCLAX COMBINATION." @default.
• W4385667085 doi "https://doi.org/10.1097/01.hs9.0000971256.60488.02" @default.
• W4385667085 hasPublicationYear "2023" @default.
• W4385667085 type Work @default.
• W4385667085 citedByCount "0" @default.
• W4385667085 crossrefType "journal-article" @default.
• W4385667085 hasAuthorship W4385667085A5010173185 @default.
• W4385667085 hasAuthorship W4385667085A5016122215 @default.
• W4385667085 hasAuthorship W4385667085A5026531372 @default.
• W4385667085 hasAuthorship W4385667085A5031977714 @default.
• W4385667085 hasAuthorship W4385667085A5045486705 @default.
• W4385667085 hasAuthorship W4385667085A5045707345 @default.
• W4385667085 hasAuthorship W4385667085A5051605599 @default.
• W4385667085 hasAuthorship W4385667085A5053239525 @default.
• W4385667085 hasAuthorship W4385667085A5059022907 @default.
• W4385667085 hasAuthorship W4385667085A5062305482 @default.
• W4385667085 hasAuthorship W4385667085A5063349306 @default.
• W4385667085 hasAuthorship W4385667085A5065205435 @default.
• W4385667085 hasAuthorship W4385667085A5078197703 @default.
• W4385667085 hasAuthorship W4385667085A5082685353 @default.
• W4385667085 hasBestOaLocation W43856670851 @default.
• W4385667085 hasConcept C126322002 @default.
• W4385667085 hasConcept C143998085 @default.
• W4385667085 hasConcept C197934379 @default.
• W4385667085 hasConcept C2777525834 @default.
• W4385667085 hasConcept C2777607594 @default.
• W4385667085 hasConcept C2777938653 @default.
• W4385667085 hasConcept C2778461978 @default.
• W4385667085 hasConcept C2779338263 @default.
• W4385667085 hasConcept C2779675984 @default.
• W4385667085 hasConcept C2779878957 @default.
• W4385667085 hasConcept C2780653079 @default.
• W4385667085 hasConcept C2781413609 @default.
• W4385667085 hasConcept C2781442060 @default.
• W4385667085 hasConcept C71924100 @default.
• W4385667085 hasConcept C90924648 @default.
• W4385667085 hasConceptScore W4385667085C126322002 @default.
• W4385667085 hasConceptScore W4385667085C143998085 @default.
• W4385667085 hasConceptScore W4385667085C197934379 @default.
• W4385667085 hasConceptScore W4385667085C2777525834 @default.
• W4385667085 hasConceptScore W4385667085C2777607594 @default.
• W4385667085 hasConceptScore W4385667085C2777938653 @default.
• W4385667085 hasConceptScore W4385667085C2778461978 @default.
• W4385667085 hasConceptScore W4385667085C2779338263 @default.
• W4385667085 hasConceptScore W4385667085C2779675984 @default.
• W4385667085 hasConceptScore W4385667085C2779878957 @default.
• W4385667085 hasConceptScore W4385667085C2780653079 @default.
• W4385667085 hasConceptScore W4385667085C2781413609 @default.
• W4385667085 hasConceptScore W4385667085C2781442060 @default.
• W4385667085 hasConceptScore W4385667085C71924100 @default.
• W4385667085 hasConceptScore W4385667085C90924648 @default.
• W4385667085 hasIssue "S3" @default.
• W4385667085 hasLocation W43856670851 @default.
• W4385667085 hasLocation W43856670852 @default.
• W4385667085 hasOpenAccess W4385667085 @default.
• W4385667085 hasPrimaryLocation W43856670851 @default.
• W4385667085 hasRelatedWork W2558110451 @default.
• W4385667085 hasRelatedWork W2735082830 @default.
• W4385667085 hasRelatedWork W2914400539 @default.
• W4385667085 hasRelatedWork W2988655741 @default.
• W4385667085 hasRelatedWork W2999683004 @default.
• W4385667085 hasRelatedWork W4283518388 @default.
• W4385667085 hasRelatedWork W4301390931 @default.
• W4385667085 hasRelatedWork W4310119455 @default.
• W4385667085 hasRelatedWork W4380186961 @default.
• W4385667085 hasRelatedWork W4385667085 @default.
• W4385667085 hasVolume "7" @default.
• W4385667085 isParatext "false" @default.
• W4385667085 isRetracted "false" @default.
• W4385667085 workType "article" @default.